Market Overview

Benzinga's Top #PreMarket Losers


Sunesis Pharmaceuticals (NASDAQ: SNSS) shares slipped 63.10% to $2.45 in pre-market trading as pivotal Phase 3 VALOR trial of acute myeloid leukemia treatment did not meet primary endpoint.

Alcobra (NASDAQ: ADHD) dropped 40.04% to $8.46 in pre-market trading following the announcement of topline results from Phase III study of MDX in adult ADHD.

EZchip Semiconductor (NASDAQ: EZCH) shares dropped 8.94% to $22.52 in pre-market trading after the company lowered its Q3 sales forecast.

H&R Block (NYSE: HRB) fell 6.10% to $29.73 in pre-market trading as the company announced that the regulatory approval process for the company's deal with BofI Federal Bank won't be completed this year.

Posted-In: PreMarket LosersNews Movers & Shakers Pre-Market Outlook Markets


Related Articles (EZCH + ADHD)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

SunTrust Robinson Humphrey Initiates Cogent Communications At Neutral

Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial Of ALD403 Published In Lancet Neurology Demonstrates ALD403 Effective In The Preventive Treatment Of Migraine